

EXHIBIT 1

IN THE UNITED STATES DISTRICT COURT
DISTRICT OF DELAWARE

_____)	
THE PROCTER & GAMBLE COMPANY,)	
)	
Plaintiff,)	
)	
v.)	
)	Civil Action No. 04-940 (JJF)
)	
TEVA PHARMACEUTICALS USA, INC.)	
)	
Defendant.)	
_____)	

JOINT STATEMENT OF ADMITTED FACTS

1. Plaintiff The Procter and Gamble Company ("Procter and Gamble") is a corporation incorporated under the laws of the State of Ohio with its principal place of business at 1 Procter and Gamble Plaza, Cincinnati, Ohio.
2. Defendant Teva Pharmaceuticals USA, Inc. ("Teva USA") is a corporation incorporated under the laws of the State of Delaware, with its principal place of business at 1090 Horsham Road, North Wales, Pennsylvania.
3. For purposes of this litigation only, Teva USA does not contest that it is subject to personal jurisdiction in Delaware.
4. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391 and 1400(b).
5. On December 21, 1984, Procter and Gamble filed United States patent application Ser. No. 684,543 (the '543 application).

6. Procter and Gamble is the assignee of the '543 application.
7. On June 6, 1985, Procter and Gamble filed United States patent application Ser. No. 741,976 (the '976 application).
8. Procter and Gamble is the assignee of the '976 application.
9. On December 6, 1985, Procter and Gamble filed a continuation-in-part of the '543 application which was United States patent application Ser. No. 806,155 (the '155 application).
10. Procter and Gamble is the assignee of the '155 application.
11. On August 2, 1988, the '976 application issued as United States Patent No. 4,761,406 (the '406 patent).
12. The '406 patent is owned by Procter and Gamble.
13. On December 10, 1996, the '155 application issued as United States Patent No. 5,583,122 (the '122 patent).
14. The '122 patent is owned by Procter and Gamble.
15. Procter and Gamble received FDA approval for the use of 30 mg Actonel tablets for treatment of Paget's Disease on March 27, 1998; 5 mg Actonel tablets for treatment of osteoporosis on April 14, 2000; and 35 mg Actonel tablets for treatment of osteoporosis on May 17, 2002.

16. The FDA's official publication of approved drugs, the "Orange Book," lists Actonel and identifies the '122 patent as one of the patents which Procter and Gamble has represented to the FDA covers Procter and Gamble's 5 mg, 30 mg and 35 mg risedronate sodium tablets.

17. Teva USA filed Abbreviated New Drug Application ("ANDA") No. 77-132 for approval to market 5 mg, 30 mg and 35 mg risedronate sodium tablets prior to the expiration of the '122 patent.

18. For purposes of this litigation only, Teva USA has agreed to not contest that the marketing in the United States of Teva USA's proposed 5mg, 30 mg and 35 mg risedronate sodium tablets in accordance with ANDA No. 77-132 would infringe claims 4, 12, 14, 16 and 23 of the '122 patent if those claims are valid and enforceable.

EXHIBIT 2

.

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

THE PROCTER & GAMBLE COMPANY,)	
)	
Plaintiff,)	
)	
v.)	Civil Action No. 04-940-JJF
)	
TEVA PHARMACEUTICALS USA, INC.,)	
)	
Defendant.)	

**THE PROCTER & GAMBLE COMPANY'S STATEMENT
OF ISSUES OF FACT THAT REMAIN TO BE LITIGATED**

The operative claims of this matter are set forth in The Procter & Gamble Company's ("P&G's") First Amended Complaint, which alleged infringement of United States Patent No. 5,583,122 (the "'122 patent") by Teva Pharmaceuticals USA, Inc. ("Teva"). In response to the First Amended Complaint, Teva asserted various defenses, including non-infringement and invalidity of the '122 patent under 35 U.S.C. §§ 102, 103, and 112.

Subsequently, Teva stipulated to infringement for purposes of this litigation. As a result, the remaining issue of law is Teva's assertion that the '122 patent is invalid, an issue on which Teva alone bears the initial burden of proof. Therefore, P&G has no burden of production or proof unless and until Teva meets its burden of establishing a *prima facie* case of patent invalidity. Only if Teva establishes a *prima facie* case would P&G be required to present rebuttal evidence that the '122 patent is indeed valid. If Teva is unable to meet its burden, P&G would have no need to present rebuttal evidence of validity.

Thus, P&G's identification of the issues of fact that remain to be litigated is based on P&G's current understanding of the arguments Teva is likely to make in attempting to establish a *prima facie* case of invalidity, based upon the pleadings and discovery in the action to date. To the extent that Teva intends or attempts to introduce different or additional facts to meet its burden of proof, P&G reserves its rights to contest those facts, and to present any and all rebuttal evidence in response to those facts, and will not be bound by the summary of remaining facts presented herein.

Based on P&G's current understanding of Teva's remaining defenses, P&G believes the following issues of fact remain to be litigated:

1. Whether U.S. Patent No. 4,761,406 (the "406 patent") is prior art to the '122 patent;
2. Whether United States Patent Application Serial No. 684,543, of which the '122 patent is a continuation-in-part, provides sufficient written description for the asserted claims of the '122 patent;
3. Whether the inventions in the asserted claims of the '122 patent were conceived and/or reduced to practice before the filing of the '406 patent application;
4. Whether the prior art asserted by Teva anticipates the asserted claims of the '122 patent;
5. Whether the scope and content of the prior art cited by Teva militate against a finding of obviousness;
6. Whether the differences between the prior art cited by Teva and the claims militate against a finding of obviousness;
7. What is the level of ordinary skill in the relevant art;

8. Whether Teva has made a showing of a suggestion or motivation to combine the teachings of references cited by Teva;

9. Whether secondary considerations of non-obviousness, such as unexpected results, commercial success, long felt but unsolved need, failure of others and copying, militate against a finding that the '122 patent is obvious;

10. Whether the delay in issuance of the '122 patent was occasioned by proceedings in the United States Patent and Trademark Office, and not caused by the applicant or assignee;

11. Whether the claims of the '122 patent and the '406 patent could have been filed in one application;

12. Whether the scope and content of the claims in the '122 patent militate against a finding of obviousness of the claims of the '406 patent;

13. Whether the differences between the claims of the '122 patent and the claims of the '406 patent militate against a finding of obviousness of the claims of the '406 patent;

14. Whether the scope and content of the claims in the '406 patent militate against a finding of obviousness of the claims of the '122 patent;

15. Whether the differences between the claims of the '406 patent and the claims of the '122 patent militate against a finding of obviousness of the claims of the '122 patent;

16. Whether secondary considerations of non-obviousness, such as unexpected results, commercial success, long felt but unsolved need, failure of others and copying, militate against a finding that the claims of the '122 patent are obvious in view of the claims of the '406 patent; and

17. Whether Teva's expert, Dr. Lenz, qualifies as one of ordinary skill in the art.

EXHIBIT 3

IN THE UNITED STATES DISTRICT COURT
DISTRICT OF DELAWARE

THE PROCTER & GAMBLE COMPANY,)	
)	
Plaintiff,)	
)	
v.)	
)	Civil Action No. 04-940 (JJF)
)	
TEVA PHARMACEUTICALS USA, INC.)	
)	
Defendant.)	

**TEVA USA'S STATEMENT OF
ISSUES OF FACT REMAINING TO BE LITIGATED**

The following issues of fact remain to be litigated in the trial of this matter:

I. INVALIDITY BASED ON ANTICIPATION OR OBVIOUSNESS

- A. Whether U.S. Patent No. 4,761,406 ("the '406 patent") anticipates claims 12, and 14 of the '122 patent.
- B. The scope and content of the prior art.
- C. The differences between the prior art and the subject matter of claims 4, 12, 14, 16, and 23 of the '122 patent.
- D. The level of ordinary skill in the art to which the inventions claimed in claims 4, 12, 14, 16, and 23 of the '122 patent pertain.

II. INVALIDITY BASED ON OBVIOUSNESS-TYPE DOUBLE PATENTING

- A. The scope and content of the claimed invention of the '406 patent.
- B. The differences between the subject matter of the claims of the '406 patent and the subject matter of claims 4, 12, 14, 16, and 23 of the '122 patent.
- C. The level of ordinary skill in the art to which the inventions pertain.

EXHIBIT 4

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

_____)	
THE PROCTER & GAMBLE COMPANY,)	
)	
Plaintiff,)	
)	
v.)	Civil Action No. 04-940-JJF
)	
TEVA PHARMACEUTICALS USA, INC.,)	
)	
Defendant.)	
_____)	

**THE PROCTER & GAMBLE COMPANY'S STATEMENT
OF ISSUES OF LAW THAT REMAIN TO BE LITIGATED**

The operative claims in this matter are set forth in The Procter & Gamble Company's ("P&G") First Amended Complaint, which alleges infringement of United States Patent No. 5,583,122 (the "'122 patent") by Teva Pharmaceuticals USA, Inc. ("Teva"). In response to the First Amended Complaint, Teva asserted various defenses, including non-infringement and invalidity of the '122 patent under 35 U.S.C. §§ 102, 103, and 112.

Subsequently, Teva stipulated to infringement of claims 4, 12, 14, 16, and 23 of the '122 patent. As a result, Teva's remaining defense is that the '122 patent is invalid, an issue on which Teva alone bears the initial burden of proof. Therefore, P&G has no burden of production or proof unless and until Teva meets its burden of establishing a *prima facie* case of patent invalidity. Only if Teva was able to establish a *prima facie* case would P&G be required to present rebuttal evidence that the '122 patent is indeed valid. If Teva is unable to meet its burden, P&G would have no need to present rebuttal evidence of validity.

Thus, P&G's identification of the issues of law that remain to be litigated is based on P&G's current understanding of the arguments Teva is likely to make in attempting to establish a

prima facie case of invalidity, based upon the pleadings and discovery in the action to date. To the extent that Teva intends or attempts to introduce different or additional legal arguments to meet its burden of proof, P&G reserves its rights to contest those legal arguments, and to present any and all rebuttal evidence in response to those arguments, and will not be bound by the summary of remaining legal issues presented herein.

Based on P&G's current understanding of Teva's remaining defenses, P&G believes that the following issues of law remain to be litigated:

1. Whether Teva has met its burden of proving by clear and convincing evidence that claims 4, 12, 14, 16, and 23 (the "asserted claims") of the '122 patent are invalid;
2. Whether the '122 patent is entitled to the benefit of the filing date of the priority application, application Serial No. 684,543, as filed on December 21, 1984;
3. Whether the one-way or two-way test for obviousness-type double patenting applies to the analysis of the claims of the '122 patent and U.S. Patent No. 4,761,406;
4. Whether P&G is entitled to an injunction precluding approval of Teva USA's ANDA and the manufacture, use, sale, offering for sale, or importation of its proposed risedronate sodium monohydrate drug products until the expiration of the '122 patent; and
5. Any evidentiary issues raised by the parties' pending motions, motions *in limine*, or objections to the evidence.

EXHIBIT 5

IN THE UNITED STATES DISTRICT COURT
DISTRICT OF DELAWARE

THE PROCTER & GAMBLE COMPANY,)	
)	
Plaintiff,)	
)	
v.)	
)	Civil Action No. 04-940 (JJF)
)	
TEVA PHARMACEUTICALS USA, INC.)	
)	
Defendant.)	

**TEVA USA'S STATEMENT OF
ISSUES OF LAW REMAINING TO BE LITIGATED**

A. Whether claims 12 and 14 of the '122 patent are invalid because they are anticipated by the '406 patent.

B. Whether claims 4, 12, 14, 16, and 23 of the '122 patent are invalid under 35 U.S.C. § 103 because the differences between the subject matter of the claims of the '122 patent and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art. *In re Dillon*, 919 F.2d 688 (Fed. Cir. 1991)(*en banc*); *Merck & Co. v. Teva Pharm., USA Inc.*, 395 F.3d 1364 (Fed. Cir. 2005); *Syntex (USA) LLC v. Apotex Inc.*, 407 F.3d 1371 (Fed. Cir 2005).

C. Whether claims 4, 12, 14, 16, and 23 of the '122 patent are invalid for obviousness-type double patenting. *In re Berg*, 140 F.3d 1428 (Fed. Cir. 1998); *Eli Lilly & Co. v. Barr Labs., Inc.*, 251 F.3d 955 (Fed. Cir. 2001); *In re Dillon*, 919 F.2d 688 (Fed. Cir. 1991)(*en banc*).

EXHIBIT 6

P&G's Exhibit List and Teva USA's Objections

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 1	Returned Goods Policy	PG	7088	7088	R, H
PTX 2	Handwritten Notes	PG	10753	10757	H
PTX 3	Toxicity Screening	PG	10758	10780	H
PTX 4	Norwich Biweekly Report	PG	10781	10781	H
PTX 5	Toxicity Screening	PG	10782	10802	H
PTX 6	Laboratory Report/Chart	PG	10803	10803	H
PTX 7	Laboratory Report/Chart	PG	10804	10804	L, H
PTX 8	Laboratory Report/Chart	PG	10807	10807	L, H
PTX 9	Laboratory Report/Chart	PG	10814	10814	H
PTX 10	Laboratory Report/Chart; meeting re: screening agenda	PG	10821	10823	C, A, H, R
PTX 11	Screening Memorandum	PG	10824	10824	H
PTX 12	Schenk Results	PG	10834	10835	H
PTX 13	Norwich Biweekly Report	PG	10881	10882	H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 14	TPTX and Schenk Results	PG	10940	10940	I, R, H, A
PTX 15	Toxicity Screen Final Report	PG	11244	11253	R, H
PTX 16	Report: Pharmacology and Toxicology Information	PG	12648	12677	H
PTX 17	Preclinical Pharmacology Report	PG	12690	12720	I, R, H, A
PTX 18	Preclinical New Drug Submission	PG	12866	12869	R, H, I, A
PTX 19	Toxicology Memorandum	PG	12958	12968	H
PTX 20	Toxicity Interim Report	PG	13306	13362	I, R, H
PTX 21	Norwich R&D Report	PG	22787	22823	R, H
PTX 22	TPTX and Schenk Summary Report	PG	23091	23102	H
PTX 23	Rat Leydig Cell Tumor Model Final Report	PG	23582	23594	R, H
PTX 24	Revision in Project Protocol	PG	23595	23602	R, H
PTX 25	Oral Toxicity Final Report	PG	23918	24117	R, H, A, C
PTX 26	Laboratory Notebook	PG	24988	25344	R, H
PTX 27	Laboratory Notebook	PG	25347	25794	R, U, A, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 28	Laboratory Notebook	PG	25797	26782	R, U, A, H
PTX 29	Laboratory Notebook	PG	26783	27137	R, U, A, H
PTX 30	Comparative Assessment of Risedronate and Etidronate	PG	29038	29047	R, H, A
PTX 31	Laboratory Notebook	PG	30302	30451	R, H
PTX 32	Laboratory Notebook	PG	30452	31055	R, U, A, H
PTX 33	Laboratory Notebook	PG	31056	31667	R, U, A, H
PTX 34	Norwich Biweekly Report	PG	33662	33662	R, H
PTX 35	Norwich Biweekly Report	PG	33682	33682	R, H
PTX 36	Norwich Biweekly Report	PG	33701	33701	R, H
PTX 37	Norwich Biweekly Report	PG	33731	33731	H
PTX 38	Norwich Biweekly Report	PG	33732	33732	H
PTX 39	Norwich Biweekly Report	PG	33739	33739	R, H
PTX 40	Norwich Biweekly Report	PG	33746	33746	R, H
PTX 41	Norwich Biweekly Report	PG	33747	33747	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 42	Norwich Biweekly Report	PG	34052	34052	H
PTX 43	Norwich Biweekly Report	PG	34058	34058	R, H
PTX 44	Norwich Biweekly Report	PG	34070	34070	H
PTX 45	Norwich Biweekly Report	PG	34091	34091	H
PTX 46	Laboratory Notebook	PG	38408	38909	R, H, A, B
PTX 47	Laboratory Notebook	PG	40306	40442	R, H, A
PTX 48	Laboratory Notebook	PG	40445	40505	R, H
PTX 49	Laboratory Notebook	PG	40938	40960	R, H
PTX 50	Publication: Antiresorptive Dose – Response Relationships Across Three Generations of Bisphosphonates	PG	41447	41454	M
PTX 51	Project Proposal Memorandum	PG	41702	41708	R, H, A
PTX 52	New Phosphonate Screening Memorandum	PG	41736	41743	M
PTX 53	Publication: Binding and Antiresorptive Properties of Heterocycle – Containing Bisphosphonate Analogs: Structure Activity Relationships	PG	41746	41751	M

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 54	Norwich Biweekly Report	PG	41844	41844	H
PTX 55	Norwich Biweekly Report	PG	41845	41845	H
PTX 56	Norwich Biweekly Report	PG	41846	41846	H
PTX 57	Laboratory Notebook	PG	42566	42650	R, H, A
PTX 58	Laboratory Notebook	PG	42690	42784	C, R, H, A
PTX 59	Special Report	PG	45556	45570	H
PTX 60	Project Proposal Memorandum	PG	45850	45856	R, H, A
PTX 61	Project Proposal Memorandum	PG	45857	45863	R, H, A
PTX 62	Project Proposal Memorandum	PG	46758	46765	C, R, H, A
PTX 63	Laboratory Notebook	PG	47855	48449	R, H, A
PTX 64	Laboratory Notebook	PG	49123	49840	C, R, H, A
PTX 65	Publication: Bisphosphonates Pharmacology and Use in the Treatment of Tumour-Induced Hypercalcemic and Metastatic Bone Disease	PG	52271	52296	R, H
PTX 66	Laboratory Notebook	PG	53448	53494	I, R, H, A

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 67	Laboratory Notebook	PG	53503	53549	R, H, A
PTX 68	Laboratory Notebook	PG	53550	53792	R, H, A
PTX 69	Laboratory Notebook	PG	53793	53896	R, H, A
PTX 70	Laboratory Notebook	PG	53897	54059	R, H, A
PTX 71	Laboratory Notebook	PG	54060	54313	R, H, A
PTX 72	Laboratory Notebook	PG	54314	54510	R, H, A
PTX 73	'399 File History Document	PG	55191	55191	R, H, A, I, C
PTX 74	'399 File History Document	PG	55192	55193	R, H, A, I, C
PTX 75	'399 File History Document	PG	55195	55195	R, H, A, I, C
PTX 76	'399 File History Document	PG	55239	55257	R, H, A, I, C
PTX 77	'399 File History Document	PG	55278	55299	R, H, A, I, C
PTX 78	'399File History Document	PG	55300	55346	R, H, I, C
PTX 79	New Diphosphonate Team Meeting Memorandum	PG	55755	55758	R, H, I, C
PTX 80	Toxicity Interim Report	PG	56964	57018	H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 81	Toxicity Interim Report	PG	57030	57085	H
PTX 82	Toxicity Interim Report	PG	57086	57146	H
PTX 83	Toxicity Screen Study Design	PG	58241	58248	R, H, A
PTX 84	Product Development Report	PG	58337	58337	H
PTX 85	New Diphosphonate Team Meeting Memorandum	PG	58338	58341	R, H
PTX 86	Interim Report Memorandum	PG	58346	58352	R, H
PTX 87	Geddes Memorandum	PG	58383	58356	R, H
PTX 88	Laboratory Notebook	PG	54135	54313	I, R, H, A
PTX 89	Norwich Biweekly Report	PG	58427	58427	R, H
PTX 90	Norwich Biweekly Report	PG	58431	58431	H
PTX 91	Interim Report Memorandum	PG	58472	58477	H
PTX 92	"Appendix A"	PG	58478	58478	I, R, H, A
PTX 93	Special Products Group Memorandum	PG	58479	58491	R, H
PTX 94	Norwich Biweekly Report	PG	58496	58496	H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 95	Handwritten Notes	PG	58524	58530	R, H, A, I
PTX 96	New Disphosphonate Update Memorandum	PG	61384	61397	C, R, H, A
PTX 97	Publication: Bisphosphonates in Bone Disease	PG	63001	63073	R, 701, H
PTX 98	'399 File History Document	PG	65713	65727	R, H, A, C, I
PTX 99	'399 File History Document	PG	65728	65808	R, H, A, C, I
PTX 100	'399 File History Document	PG	65809	65863	R, H, A, C, I
PTX 101	'399 File History Document	PG	65864	65876	R, H, A
PTX 102	Comparative Hepatotoxicity Chart	PG	66216	66216	R, H, A, I
PTX 103	Toxicity Screening Schedule	PG	66281	66281	H
PTX 104	Toxicity Screening Schedule	PG	66306	66331	I, H
PTX 105	Toxicity Screening Schedule	PG	66348	66348	H
PTX 106	Toxicity Screening Schedule	PG	66349	66349	H
PTX 107	New Diphosphonate Selection Meeting Memorandum	PG	66836	66874	H
PTX 108	Charts	PG	66992	67160	R, H, A, I

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 109	Proposal Memorandum	PG	68065	68065	H
PTX 110	Charts	PG	68073	68111	I, R, H, A
PTX 111	Charts	PG	68117	68130	H
PTX 112	Bone Metabolism – Chemistry Program Report	PG	68186	68202	R, H
PTX 113	TPTX and Schenk Table	PG	68239	68241	R, H, A
PTX 114	Publication: Bisphosphonates: Structure-Activity Relationships and Therapeutic Implications	PG	68444	68485	H
PTX 115	File Wrapper '155	PG	68760	69010	C, I
PTX 116	Osteoporosis Market Information	PG	69014	69035	H
PTX 117	Interdepartmental Memorandum	PG	73217	73220	R, H
PTX 118	Ebetmo Presentation	PG	73304	73354	R, H
PTX 119	TPTX Memorandum	PG	73693	73693	R, H, A, I
PTX 120	TPTX Contract Protocol	PG	73802	73806	H
PTX 121	TPTX Correspondence	PG	73881	73881	H
PTX 122	Handwritten Notes	PG	73882	73882	H, A

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 123	TPX Correspondence and Laboratory Notebook	PG	73883	73939	H, A
PTX 124	New Diphosphonate Update Memorandum	PG	74631	74631	R, H, A, I
PTX 125	Chart	PG	74632	74632	R, H, A, I
PTX 126	Chart	PG	74633	74633	R, H, A, I
PTX 127	New Diphosphonate Meeting Memorandum	PG	74634	74636	H, I
PTX 128	New Diphosphonate Meeting Memorandum	PG	75243	75249	H
PTX 129	New Diphosphonate Meeting Memorandum	PG	75244	75249	H
PTX 130	Geddes Memorandum	PG	76986	76988	H, I
PTX 131	Project Proposal Memorandum	PG	77027	77033	R, H
PTX 132	Norwich Biweekly Report	PG	77088	77094	H
PTX 133	Norwich Biweekly Report	PG	77095	77095	R, H
PTX 134	Norwich Biweekly Report	PG	77096	77097	R, H
PTX 135	Norwich Biweekly Report	PG	77099	77099	R, H
PTX 136	Norwich Biweekly Report	PG	77110	77110	H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 137	Norwich Biweekly Report	PG	77111	77111	R, H
PTX 138	Norwich Biweekly Report	PG	77112	77112	H
PTX 139	Norwich Biweekly Report	PG	77113	77113	H
PTX 140	Norwich Biweekly Report	PG	77114	77114	H
PTX 141	Norwich Biweekly Report	PG	77115	77115	R, H
PTX 142	Norwich Biweekly Report	PG	77116	77117	H, C
PTX 143	Norwich Biweekly Report	PG	77118	77118	R, H
PTX 144	Norwich Biweekly Report	PG	77119	77119	R, H
PTX 145	Norwich Biweekly Report	PG	77120	77120	R, H
PTX 146	Laboratory Notebook	PG	78287	78407	R, H, A
PTX 147	Project Proposal Memorandum	PG	78478	78485	R, H
PTX 148	New Diphosphonate Meeting Memorandum	PG	78486	78507	H
PTX 149	TPTX and Schenk Results	PG	78508	78509	R, H
PTX 150	IMS Data	PG	78565	78570	R, H, A

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 151	Actonel Financial Information	PG	78585	78599	R, H, A
PTX 152	Actonel in the Osteoporosis Market Report	PG	78600	78688	R, H
PTX 153	Actonel in the Osteoporosis Market Report	PG	78689	78717	R, H
PTX 154	Actonel in the Osteoporosis Market Report	PG	78718	78757	R, H
PTX 155	Actonel in the Osteoporosis Market Report	PG	78758	78834	H
PTX 156	Actonel in the Osteoporosis Market Report	PG	78835	78891	H
PTX 157	Actonel in the Osteoporosis Market Report	PG	78892	78956	R, H
PTX 158	Actonel in the Osteoporosis Market Report	PG	78957	79017	R, H
PTX 159	Actonel in the Osteoporosis Market Report	PG	79018	79080	R, H
PTX 160	Actonel in the Osteoporosis Market Report	PG	79081	79143	R, H
PTX 161	Tracking Research Results	PG	79144	79211	R, H
PTX 162	Tracking Research Results	PG	79212	79281	H
PTX 163	Physician and Sales Force Analysis	PG	79282	79331	R, H
PTX 164	Compass Report	PG	79332	79384	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 165	Compass Report	PG	79385	79455	R, H
PTX 166	Compass Report	PG	79456	79525	H
PTX 167	Compass Report	PG	79526	79550	H
PTX 168	Compass Report	PG	79551	79590	R, H
PTX 169	Compass Report	PG	79591	79618	R, H
PTX 170	Compass Report	PG	79619	79655	R, H
PTX 171	Compass Report	PG	79656	79692	R, H
PTX 172	Compass Report	PG	79693	79750	R, H
PTX 173	Compass Report	PG	79751	79818	R, H
PTX 174	Compass Report	PG	79819	79847	R, H
PTX 175	Compass Report	PG	79869	79893	R, H
PTX 176	Compass Report	PG	79894	79916	R, H
PTX 177	Compass Report	PG	79917	79947	R, H
PTX 178	Compass Report	PG	79948	79970	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 179	Compass Report	PG	79971	80003	R, H
PTX 180	Compass Report	PG	80004	80029	R, H
PTX 181	Compass Report	PG	80030	80063	R, H
PTX 182	Compass Report	PG	80064	80102	H
PTX 183	Compass Report	PG	80103	80129	R, H
PTX 184	Compass Report	PG	80170	80210	R, H
PTX 185	Compass Report	PG	80211	80218	I, R, H
PTX 186	Business Review Actonel	PG	80219	80220	I, R, H
PTX 187	Compass Report	PG	80221	80224	I, R, H
PTX 188	Compass Report	PG	80225	80227	I, R, H
PTX 189	Charts	PG	80228	80235	I, R, H
PTX 190	Compass Chart	PG	80236	80238	R, H
PTX 191	Compass Chart	PG	80239	80241	R, H
PTX 192	Compass Report	PG	80242	80292	R, H, I

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 193	Chart	PG	80293	80298	R, H, I
PTX 194	Compass Report	PG	80299	80351	R, H
PTX 195	Compass Report	PG	80352	80362	R, H, C
PTX 196	Compass Report	PG	80363	80367	R, H, I
PTX 197	Compass Report	PG	80412	80414	H
PTX 198	Compass Report	PG	80510	80533	R, H
PTX 199	Compass Report	PG	80534	80568	R, H
PTX 200	Compass Report	PG	80606	80611	R, H
PTX 201	Compass Report	PG	80612	80639	R, H
PTX 202	Compass Report	PG	80640	80673	R, H
PTX 203	Compass Report	PG	80674	80677	R, H
PTX 204	Compass Report	PG	80678	80696	R, H
PTX 205	Compass Report	PG	80697	80728	R, H
PTX 206	Compass Report	PG	80729	80737	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 207	Compass Report	PG	80742	80754	R, H
PTX 208	Compass Report	PG	80755	80756	R, H
PTX 209	Compass Report	PG	80757	80800	R, H
PTX 210	Actonel Prescription Share Chart	PG	94159	94161	R, H
PTX 211	Revision in Project Protocol	PG	94162	94169	R, H
PTX 212	Revision in Project Protocol	PG	94170	94188	R, H
PTX 213	Project Protocol	PG	94189	94195	R, H
PTX 214	Protocols	PG	94196	94196	R, H, I
PTX 215	Project Protocol	PG	94197	94199	R, H
PTX 216	Project Protocol	PG	94200	94205	R, H
PTX 217	Project Protocol	PG	94206	94219	R, H
PTX 218	TPTX and Schenk Table	PG	94220	94221	R, H, I
PTX 219	Revision in Project Protocol	PG	94228	94235	R, H
PTX 220	Toxicity Final Report	PG	94236	94237	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 221	Toxicity Interim Report	PG	94238	94299	R, H
PTX 222	Toxicity Interim Report	PG	94300	94355	R, H
PTX 223	Toxicity Interim Report	PG	94356	94410	R, H
PTX 224	Chart of Expenses	PG	94413	94413	H
PTX 225	Royalty Payments	PG	94414	94414	H
PTX 226	Chart	PG	94415	94415	H
PTX 227	Chart of Expenses	PG	94698	94705	H
PTX 228	Actonel Brochure	PG	95041	95056	R, H
PTX 229	Actonel Brochure	PG	95057	95061	R, H
PTX 230	Actonel Brochure	PG	95062	95091	R, H
PTX 231	Actonel Brochure	PG	95092	95122	R, H
PTX 232	Actonel Brochure	PG	95123	95136	R, H
PTX 233	Actonel Brochure	PG	95137	95144	R, H
PTX 234	Package Insert	PG	95145	95173	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 235	Package Insert	PG	95174	95183	R, H
PTX 236	Package Insert	PG	95184	95184	R, H
PTX 237	Actonel Brochure	PG	95185	95185	R, H
PTX 238	Actonel Brochure	PG	95186	95201	R, H
PTX 239	Actonel Brochure	PG	95202	95203	R, H
PTX 240	Actonel Brochure	PG	95204	95205	R, H
PTX 241	Actonel Brochure	PG	95206	95207	R, H
PTX 242	Actonel Brochure	PG	95208	95254	R, H
PTX 243	Actonel Brochure	PG	95255	95256	R, H
PTX 244	Actonel Brochure	PG	95257	95280	R, H
PTX 245	Actonel Brochure	PG	95281	95300	R, H
PTX 246	Publication: AMA Reprint	PG	95303	95309	R, H
PTX 247	Publication: AMA Reprint	PG	95310	95321	R, H
PTX 248	Publication: Osteoporosis International	PG	95322	95332	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 249	Publication: New England Journal of Medicine	PG	95333	95341	R, H
PTX 250	Publication: Journal of Bone and Mineral Research	PG	95342	95352	R, H
PTX 251	Publication: Arthritis and Rheumatism	PG	95353	95363	R, H
PTX 252	Publication: Gastroenterology	PG	95364	95373	R, H
PTX 253	Publication: Archives of Internal Medicine	PG	95374	95380	R, H
PTX 254	Price Comparison Report	PG	95381	95382	R, H
PTX 255	Package Insert	PG	95383	95386	R, H
PTX 256	Competitive Resource Guide	PG	95387	95407	R, H
PTX 257	Publication: Osteoporosis International	PG	95408	95418	R, H
PTX 258	Clinical Study Analysis	PG	95419	95422	R, H, B
PTX 259	Publication: Journal of Bone and Mineral Research	PG	95423	95432	R, H, B
PTX 260	Clinical Study Analysis	PG	95433	95437	R, H, B
PTX 261	Publication: Arthritis and Rheumatism	PG	95438	95448	R, H
PTX 262	Clinical Study Analysis	PG	95449	95453	R, H, B

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 263	Publication: New England Journal of Medicine	PG	95454	95464	R, H
PTX 264	Clinical Study Analysis	PG	95465	95467	R, H, B
PTX 265	Publication: JAMA	PG	95468	95473	R, H
PTX 266	Clinical Study Analysis	PG	95474	95478	R, H, B
PTX 267	Publication: Gastroenterology	PG	95479	95488	R, H
PTX 268	Clinical Study Analysis	PG	95489	95493	R, H, B
PTX 269	Publication: Archives of Internal Medicine	PG	95494	95503	R, H
PTX 270	Clinical Study Analysis	PG	95504	95509	R, H, B
PTX 271	Publication: The Lancet	PG	95510	95517	R, H
PTX 272	Clinical Study Analysis	PG	95518	95521	R, H, B
PTX 273	Publication: JAMA	PG	95522	95528	R, H
PTX 274	Clinical Study Analysis	PG	95529	95534	R, H, B
PTX 275	Publication: Osteoporosis International	PG	95535	95542	R, H
PTX 276	Clinical Study Analysis	PG	95543	95546	R, H, B

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 277	Publication: New England Journal of Medicine	PG	95547	95557	R, H
PTX 278	Clinical Study Analysis	PG	95558	95563	R, H, B
PTX 279	Publication: New England Journal of Medicine	PG	95564	95573	R, H
PTX 280	Clinical Study Analysis	PG	95574	95583	R, H, C, B
PTX 281	Publication: JMCP	PG	95584	95589	R, H, C
PTX 282	Clinical Study Analysis	PG	95590	95596	R, H, B
PTX 283	Medical Reprint Analysis	PG	95597	95601	R, H, B
PTX 284	Publication: American Journal of Medicine	PG	95602	95614	R, H
PTX 285	Clinical Study Analysis	PG	95615	95619	R, H, B
PTX 286	Publication: JAMA	PG	95620	95629	R, H
PTX 287	Evista Brochure	PG	95630	95649	R, H
PTX 288	Clinical Study Analysis	PG	95650	95656	R, H, B
PTX 289	Publication: New England Journal of Medicine	PG	95657	95666	R, H
PTX 290	Clinical Study Analysis	PG	95667	95669	R, H, B

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 291	Publication: Clinical Endocrinology and Metabolism	PG	95670	95679	R, H
PTX 292	Clinical Study Analysis	PG	95680	95685	R, H, B
PTX 293	Publication: Journal of Bone and Mineral Research	PG	95686	95692	R, H
PTX 294	P&G Publication: OsteoNews	PG	95693	95726	R, H, B
PTX 295	Clinical Study Analysis	PG	95727	95733	R, H, B
PTX 296	Publication: Journal of Bone and Mineral Research	PG	95734	95741	R, H
PTX 297	P&G Marketing Plan	PG	95742	95767	R, H
PTX 298	P&G Marketing Plan	PG	95768	95785	R, H
PTX 299	P&G Marketing Plan	PG	95786	95822	R, H
PTX 300	P&G Marketing Plan	PG	95823	95860	R, H
PTX 301	P&G Marketing Plan	PG	95861	95897	R, H
PTX 302	P&G Marketing Plan	PG	95898	95959	R, H
PTX 303	P&G Marketing Plan	PG	95960	95997	R, H
PTX 304	P&G Marketing Plan	PG	95998	96069	R, H, C

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 305	Actonel Brochure	PG	96070	96084	R, H
PTX 306	Actonel Brochure	PG	96085	96087	R, H
PTX 307	Actonel Brochure	PG	96088	96093	R, H
PTX 308	Actonel Brochure	PG	96094	96099	R, H
PTX 309	Actonel Brochure	PG	96100	96113	R, H
PTX 310	Actonel Brochure	PG	96114	96129	R, H
PTX 311	Retail Customer Correspondence	PG	96130	96158	R, H
PTX 312	Transmittal Form	PG	96159	96160	R, H
PTX 313	Physician Correspondence	PG	96161	96161	R, H
PTX 314	Actonel Website Information	PG	96162	96190	R, H
PTX 315	Actonel Website Information	PG	96191	96211	R, H
PTX 316	Actonel Brochure	PG	96212	96215	R, H
PTX 317	Actonel Brochure	PG	96216	96232	R, H
PTX 318	Actonel Insert	PG	96233	96237	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 319	Prescription Data	PG	187876	187880	H
PTX 320	Prescription Data	PG	187881	187885	H
PTX 321	Prescription Data	PG	187886	187889	H
PTX 322	Publication - Mizik, Natalie and Robert Jacobson (2004), Are Physicians Easy Marks?: Quantifying the Effects of Detailing and Sampling on New Prescriptions, Management Science 50(12)	PG	187890	187901	R, H
PTX 323	Publication - Booth, Bruce and Rodney Zimmel, The Search for Blockbuster Drugs: Efficacy Isn't Everything", The McKinsey Quarterly, February 2006	PG	187902	187905	H
PTX 324	Publication - Campbell, Margaret C., and Anna Kirmani (2000) "Consumers' Use of Persuasion Knowledge: The Effects of Accessibility and Cognitive Capacity on Perceptions of an Influence Agent," Journal of Consumer Research, 27, June, 69-83	PG	187906	187918	R, H
PTX 325	Publication - Cooper, Robert G. (2001), Winning at New Products, 3rd Edition, Perseus Publishing	PG	187919	187922	H
PTX 326	Publication - Rogers, Everett M. (1983), The Diffusion of Innovations, Free Press	PG	187923	187927	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 327	Publication - Kotler, Philip and Gary Armstrong (2004), Principles of Marketing, 10th Edition, Prentice Hall	PG	187928	187932	R, H
PTX 328	Publication - Lovallo and Kahneman, Harvard Business Review (Harvard Business Review, July, 2003, pp 56 – 63)	PG	187933	187940	R, H
PTX 329	Publication - R. Muhlbauer and H. Fleisch, Effect of Various Polyphosphonates on Ectopic Calcification and Bone Resorption in Rats, 5 Mineral Electrolyte Metab. 296-303 (1981))	PG	190663	190670	R, H
PTX 330	Publication - D.M. Morton, Requirements for the toxicological testing of drugs in the USA, Canada and Japan, Testing for Toxicity, in J.W. Gorrod (Ed.), Taylor and Francis, Ltd, London (1981)	PG	190671	190679	R, H
PTX 331	Publication - Animal Testing Policy, U.S. Consumer Product Safety Commission, 49 Fed. Reg. 22522-22523 (1984)	PG	190680	190681	R, H
PTX 332	Publication - LD50 Test Policy, FDA, 53 Fed. Reg. 39650-39651 (1988)	PG	190682	190683	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 333	Publication - M.E. Hurtt, G.D. Cappon,, and A. Browning, Proposal for a tiered approach to developmental toxicity testing for veterinary pharmaceutical products for food producing animals, 41(5) Food Chem. Toxicol. 611-619 (2003)	PG	190684	190692	R, H
PTX 334	Publication - Testing of potential environmental toxins, Toxicity Testing for Assessment of Environmental Agents: Interim Report, Board of Environmental Studies and Toxicology, The U.S. National Academy of Sciences Press (2006)	PG	190693	190962	R, H
PTX 335	Publication - P.D. Delmas et al., Long term effects of dicloromethylene diphosphonate in Paget's disease in bone, 54 J. Clin. Endocrinol. Metab. 837-844 (1982)	PG	190963	190970	R, H
PTX 336	Publication - J.M. Lane and V.J. Vigorita, Osteoporosis, 65 J. Bone Jt. Surg. Am. 274-278 (1983)	PG	190971	190975	R, H
PTX 337	Publication - L.G. Raisz, Osteoporosis, 30 J. Am. Geriatr. Soc. 127-138 (1982)	PG	190976	190987	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 338	Report - L.G. Raisz and A. Johannesson, Pathogenesis, prevention and therapy of osteoporosis, 15 J. Med. 267-278 (1984)	PG	190988	190999	R, H
PTX 339	Publication - Fleisch, H., Bisaz, S., Isolation from urine of pyrophosphate, a calcification inhibitor, 203 Am. J. Physiol. 203:671-675 (1962)	PG	191000	191004	R, H
PTX 340	Publication - Fleisch, H. and Neuman, W.F. Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase. 200 Am. J. Physiol. 1296-1300 (1961)	PG	191005	191009	R, H
PTX 341	Publication - Russell, R.G.G. Excretion of inorganic pyrophosphate in hypophosphatasia, 2 Lancet 461-464 (1965)	PG	191010	191013	R, H
PTX 342	Publication - Russell, R.G.G. and Smith, R., Diphosphonates: experimental and clinical aspects, 55B J. Bone Jt. Surg. 66-86 (1973)	PG	191014	191034	R, H
PTX 343	Publication - Fleisch, H. Bisphosphonates: Mechanisms of action, 19 Endocrine Reviews 80-100 (1998)	PG	191035	191055	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 344	Publication - Fleisch, H., Russell, R.G.G., Bisaz, S., Casey, P.A., Muhlbauer R.C., The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo, 2 Calcif. Tissue Res. 10-10A (1968)	PG	191056	191057	R, H
PTX 345	Publication - Fleisch, H., Russell, R.G.G., Bisaz, S., Muhlbauer, R.C., Williams, D.A., The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo, 1 Eur. J. Clin. Invest. 12-18 (1970)	PG	191058	191064	R, H
PTX 346	Dissertation - Miller, S.C., Effects of ethane-1-hydroxy-1,1-diphosphonate and dichloromethylene diphosphonate on bone of the growing rat. Ph.D. Dissertation, University of Utah, August 1974.	PG	191065	191149	R, H
PTX 347	Publication - Miller, S.C. and W.S.S. Jee, Ethane-1-hydroxy-1,1-diphosphonate (EHDP) effects on growth and modeling of the rat tibia, 18 Calcif. Tiss. Res., 215-231 (1975)	PG	191150	191159	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 348	Publication - Miller, S.C., Jee W.S.S., Kimmel D.B. and Woodbury L., Ethane-1,1-hydroxy-1,1-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei, 22 Calcif. Tiss. Res. 243-252 (1977)	PG	191160	191167	R, H
PTX 349	Publication - Miller, S.C. and Jee W.S.S., The comparative effects of dichloromethylene diphosphonate (Cl2MDP) and ethane-1,1-hydroxy-1,1-diphosphonate (EHDP) on growth and modeling of the rat tibia, 23 Calcif. Tiss. Res. 207-214 (1977)	PG	191168	191190	R, H
PTX 350	Publication - Boonekamp, P.M., Lowik, CWGM, van der Wee-Pals, L.J.A., van Wijck-van Lennep, M.L.L., Bijvoet, O.L.M., Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group, 2 Bone Miner. 29-42 (1987)	PG	191191	191204	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 351	Publication - Muhlbauer, R.C., Baus, F., Schenk, R., Janner, M., Bostes, E., Strein, K., Fleisch, H., BM21.0955, a potent new bisphosphonate to inhibit bone resorption. 6 J. Bone Miner. Res. 1003-1011 (1991)	PG	191205	191213	R, H
PTX 352	Publication - Rogers, M.J., Xiong, X., Brown, R.J., Watts, D.J., Russell, R.G.G., Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae, 47 Molecular Pharmacology 398-402 (1995)	PG	191214	191218	R, H
PTX 353	Publication - Russell, R.G.G., Rogers, M.J., Bisphosphonates: From the laboratory to the clinic and back again, 25 Bone 97-106 (1999)	PG	191219	191228	R, H
PTX 354	Publication - Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ., Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, 296 J Pharmacol Exp Ther. 235-242 (2001)	PG	191229	191236	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 355	Publication – Fleisch, Bone Resorption, Metastasis, and Diphosphonates, Monographs of The Mario Negri Institute for Pharmacological Research, Milan, Italy, based on a Symposium held June 1984, Garattini (ed.), Raven Press, New York, pp. 33-40 (1985)	PG	191237	191244	R, H
PTX 356	Publication - Shinoda et al., Structure-Activity Relationships of Various Bisphosphonates, 35 Calcif. Tissue Int. 87-99 (1983))	PG	191245	191257	R, H
PTX 357	Publication - Albert L. Lehninger, Biochemistry, Worth Publishers, Inc. (1970)	PG	191258	191260	R, H
PTX 358	Publication – Odvina et al., in Journal of Clinical Endocrinology and Metabolism, 90:1294-1301 (2005)	PG	191261	191268	R, H
PTX 359	Competitive Intelligence Presentation	PGK	1	124	R, H
PTX 360	Osteoporosis Overview	PGK	175	336	R, H
PTX 361	Risedronate Overview	PGK	2413	2618	R, H, B
PTX 362	Actonel Forecasts	PGK	4120	4150	H
PTX 363	Planning Presentation	PGK	9240	9341	H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 364	Actonel PMO	PGK	9353	9363	H
PTX 365	Risedronate Report	PGK	9371	9377	R, H
PTX 366	Revised Risedronate Report	PGK	9378	9382	R, H
PTX 367	Risedronate Business Opportunity	PGK	9389	9395	H
PTX 368	Risedronate Business Strategy	PGK	9396	9403	H
PTX 369	Risedronate Strategy	PGK	9404	9411	H
PTX 370	P&G Agenda	PGK	9577	9631	R, H
PTX 371	Competitor Chart	PGK	10051	10054	R, H
PTX 372	Competitive Comparison Chart	PGK	10055	10057	R, H
PTX 373	Competitive Intelligence Presentation	PGK	10310	10357	R, H
PTX 374	External Review of P&G's Pharmaceuticals Business	PGK	10466	10643	R, H
PTX 375	Lufkin Presentation	PGK	13237	13318	R, H
PTX 376	Product Overviews Report	PGK	13319	13403	R, H
PTX 377	Actonel Brand Presentation	PGK	13453	13526	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 378	Marketing Plan Agenda	PGK	13527	13605	R, H
PTX 379	Actonel Business Plan	PGK	13728	13772	R, H
PTX 380	U.S. Launch Plan 2000	PGK	13799	13805	R, H
PTX 381	US Osteoporosis Market History Memorandum	PGK	13813	13817	R, H, C
PTX 382	Actonel U.S. Business Review Memorandum	PGK	13909	13913	R, H
PTX 383	Exhibits to Business Review	PGK	13914	13952	R, H
PTX 384	Launch Tracking Research Report	PGK	13992	14054	R, H
PTX 385	Actonel Quarterly Launch Tracking	PGK	14055	14148	R, H
PTX 386	U.S. Emerging Osteoporosis Therapeutics Markets	PGK	14545	14712	R, H
PTX 387	1999 Actonel Market Review	PGK	14716	14814	R, H
PTX 388	Actonel Quarterly Launch Tracking	PGK	14815	14908	R, H
PTX 389	Actonel Quarterly Launch Tracking	PGK	14909	15002	R, H
PTX 390	Actonel Quarterly Launch Tracking	PGK	15003	15084	R, H
PTX 391	Actonel Quarterly Launch Tracking	PGK	15153	15234	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 392	Actonel Product Monograph	PGK	15481	15541	H, B
PTX 393	Actonel Advertisement	PGK	15646	15648	R, H
PTX 394	Actonel Quarterly Launch Tracking	PGK	17189	17266	R, H
PTX 395	Presentation Agenda	PGK	17267	17604	R, H
PTX 396	Actonel Forecasts	PGK	17605	17638	R, H
PTX 397	Actonel U.S. Business Review Memorandum	PGK	18158	18162	R, H
PTX 398	Competitor Product Information	PGK	22286	22321	R, H
PTX 399	P&G Pharmaceuticals Quarterly Letter	PGK	22843	22847	R, H
PTX 400	Competitive Update Memorandum	PGK	22871	22874	R, H
PTX 401	Competitive Update Memorandum	PGK	22875	22877	R, H
PTX 402	Fosamax Marketing Plan and Results Memorandum	PGK	22878	22907	R, H
PTX 403	CI Monthly Summary Memorandum	PGK	22939	22942	R, H
PTX 404	CI Monthly Summary Memorandum	PGK	22944	22947	R, H
PTX 405	Merck Company Profile	PGK	23057	23064	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 406	IMS Report	PGK	23163	23168	R, H
PTX 407	Neven E-Mail	PGK	23172	23175	R, H
PTX 408	Osteoporosis Market Competitive Update	PGK	23317	23322	R, H
PTX 409	CI Monthly Summary Memorandum	PGK	23326	23328	R, H
PTX 410	Actonel Competitive Issues Memorandum	PGK	23422	23424	R, H
PTX 411	Competitive Set Summary	PGK	23470	23471	R, H
PTX 412	Publication: Credit Suisse	PGK	23488	23496	H
PTX 413	Actonel Competitive Issues Memorandum	PGK	23532	23534	R, H
PTX 414	Dyck E-Mail	PGK	23537	23537	R, H
PTX 415	E-Mail attaching Robertson Stevens Report	PGK	23627	23631	R, H
PTX 416	TEVA ANDA	Teva	1	4880	R
PTX 417		File Wrapper '543 Patent Interference	None	None	M
PTX 418	File Wrapper '399	Interference	None	None	M
PTX 419	Teva's Paragraph IV Notification	None	None	None	R

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 420	Teva's Stipulation Of Infringement	None	None	None	R
PTX 421	Selected Portions of the Orange Book	None	None	None	M
PTX 422	Handwritten Notes	PG	10930	10934	R, H, A
PTX 423	Project Protocol	PG	11221	11224	R, H
PTX 424	Norwich R&D Department Report	PG	23190	23201	R, H
PTX 425	Pathology/Toxicology Section Final Report	PG	23202	23217	R, H
PTX 426	Toxicity Interim Report	PG	27818	28482	R, H
PTX 427	Rebuttal Expert Report of Dr. Bilizikian	None	None	None	R, H
PTX 428	CV of Dr. Bilizikian	None	None	None	R, H
PTX 429	Rebuttal Expert Report of Dr. McKenna	None	None	None	R, H
PTX 430	CV of Dr. McKenna	None	None	None	R, H
PTX 431	Rebuttal Expert Report of Dr. Miller	None	None	None	R, H
PTX 432	CV of Dr. Miller	None	None	None	R, H
PTX 433	Expert Report of Dr. Smith	None	None	None	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 434	CV of Dr. Smith	None	None	None	R, H
PTX 435	Exhibit 3 to the Expert Report of Dr. Smith	None	None	None	R, H, B
PTX 436	Exhibit 4 to the Expert Report of Dr. Smith	None	None	None	R, H, B
PTX 437	Exhibit 5 to the Expert Report of Dr. Smith	None	None	None	R, H, B
PTX 438	Exhibit 6 to the Expert Report of Dr. Smith	None	None	None	R, H, B
PTX 439	Rebuttal Expert Report of Mr. Voight	None	None	None	R, H
PTX 440	CV of Mr. Voight	None	None	None	R, H
PTX 441	Rebuttal Expert Report of Dr. Wiener	None	None	None	R, H
PTX 442	CV of Dr. Wiener	None	None	None	R, H
PTX 443	Procter & Gambles First Set of Interrogatories to Teva	None	None	None	R, H
PTX 444	8/29/05 Defendant's Responses to Plaintiff Procter & Gamble's First Set of Interrogatories	None	None	None	R
PTX 445	10/06/05 Teva's Supplemental Responses to P&G's First Set of Interrogatories (1-11)	None	None	None	R
PTX 446	P&G's First Requests for Admission to Teva	None	None	None	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 447	10/25/05 Teva's Responses to P&G's First Request for Admissions (1-28)	None	None	None	R
PTX 448	Teva's Initial Disclosures	None	None	None	R
PTX 449	P&G's First Amended Complaint	None	None	None	H
PTX 450	Teva's Answer to the First Amended Complaint	None	None	None	H
PTX 451	Publication: Sietsema et al, Drugs Exptl. Clin. Res. XV(9):389-396 (1989):	PG	60390	60398	R, H
PTX 452	Note re: TPTX & Schenk Results	PG	10930	10934	R, H, A
PTX 453	Research and Development Report	PG	23190	23201	R, H
PTX 454	Final Report by D.F. Eastman - June 25, 1985	PG	23202	23217	R, H
PTX 455	Final Report by D.F. Eastman - June 25, 1985	PG	23218	23234	R, H
PTX 456	Interim Report by D.F. Eastman - July 26, 1985	PG	27820	28482	R, H, U
PTX 457	U.S. Patent No. 4,687,767	PG	60374	60380	H
PTX 458	Publication: Shinoda et al, Calcified Tissue International 1983 (35):87-99	PG	191245	191257	R, H
PTX 459	Publication: Fleisch, "Chemistry and Mechanisms of Action of Bisphosphonates," (1985) pp 33-40.	PG	191237	191244	H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 460	Publication: Fleisch, Drugs 42(6):919-944 (1991)	PG	52271	52296	R, H
PTX 461	Publication: Fleisch, Bisphosphonates in Bone Disease (1993)	PG	63001	63073	R, H
PTX 462	US Patent No. 3,919,199		(PX11)		R, H
PTX 463	FDA Policy Statement		(PX12)		R, H, U
PTX 464	US Patent No. 4,013,644		(PX13)		R, H
PTX 465	U.S. Patent 4,013,666		(PX14)		R, H
PTX 466	Handwritten chemical structures		(PX15)		R, H
PTX 467	H. Fleisch Letter and Report	PG	10735	10742	R, H
PTX 468	Publication: Luckman et al, "Heterocycle-Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure—Activity Relationships in J774 Macrophages," Journal of Bone and Mineral Research, (1998) pp. 1668-1678				NP, M
PTX 469	Publication: Russell, "Bisphosphonates, From Bench to Bedside," (2006) pp. 367-401.				NP, M

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 470	Publication: Nancollas et al, "Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite," Bone 38 (2006) pp. 617-627.				NP, M
PTX 471	Publication: Kavanagh et al, "The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs," PNAS (2006) pp. 7829-7834.				NP, M
PTX 472	Publication: Rondeau et al, "Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs," ChemMedChem (2006) pp. 267-273.				NP, M
PTX 473	Publication: Ebetino et al, "Bisphosphonate antiresorptive structure-activity relationships," Bisphosphonate on bones (1995) pp. 139-153.				H
PTX 474	Publication: Ebetino et al, "Elucidation of a Pharmacophore for the Bisphosphonate Mechanism of Bone Antiresorptive Activity," Phosphorus, Sulfur, and Silicon, (1996) Vols. 109-110, pp. 217-220.				NP, M

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 475	Publication: McOsker et al, "Use of Rectilinear Single-Photon Absorptiometry to Evaluate Bone-Mass Changes in Rats" Cells and Materials, Supplement 1, (1991) pp. 93-104.				NP, M
PTX 476	Test Substances Characterization Report, F. H. Ebetino, 10/14/85	PG	6020	6021	R, H, A, C
PTX 477	Norwich Eaton submission, 8/6/85	PG	6341	6342	R, H, C
PTX 478	Report (H. Fleisch) 11/8/85	PG	10733	10734	R, H
PTX 479	Project Proposal by Project Director: J.A. Bevan, Ph.D.	PG	10984	10987	R, H
PTX 480	Project Protocol (K.W.Buckingham) "Oral Dosing of diphosphonates . . ."	PG	11221	11224	R, H
PTX 481	Interdepartmental Report: Safety Review Meeting on 2-Pyridyl . . . (D.F. Eastman)	PG	12928	12930	R, H
PTX 482	Final Report of D.F. Eastman; Project 850.09.00-TT	PG	12991	13108	R, H, A
PTX 483	Project Protocol, Project 850.09.00-TT, 8/9/85	PG	13109	13122	R, H, A, I
PTX 484	R&D Report: "Oral 2-Pyridyl EDP . . ." Harry M. Olson	PG	23189	23189	R, H
PTX 485	Project Protocol (D.F. Eastman) "Test for Chemical . . ."	PG	23266	23278	R, H
PTX 486	Pathology/Toxicology Final Report "L5178Y Mouse . . ." (D. F. Eastman)	PG	23279	23314	R, H, A, C

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 487	RT&D Report: "Diphosphonate Efficacy . . ." Harry M. Olson	PG	23377	23392	R, H
PTX 488	R&D Report: Oral 2-Pyridyl . . . 6/4/85	PG	28986	28986	R, H
PTX 489	R&D Report: Effects of Oral Gavage . . . K. Y. Johnson et al., Notebook VT 6035-46-77, 6/3/85	PG	28987	28998	R, H
PTX 490	R&D Report: Diphosphonate Efficacy . . . H.M. Olson, 6/4/85	PG	28999	28999	R, H
PTX 491	Protocol Amendment, 8/1/85	PG	29015	29015	R, H
PTX 492	Protocol Amendment 5/8/85	PG	29035	29035	R, H, I
PTX 493	Protocol Amendment 5/13/85	PG	29036	29036	R, H, I
PTX 494	Final Report Drug Safety Assessment Dept. (D.F. Eastman) 7/15/85	PG	29048	29347	R, H, I
PTX 495	R&D Dept. Rept. (Johnson et al.) 6/3/85	PG	58293	58293	R, H
PTX 496	Memo: J.J. Benedict for period ending 6/5/85	PG	58377	58377	R, H
PTX 497	K. Y. Johnson Report, 5/8/85	PG	73692	73692	R, H
PTX 498	TPTX-Arizona - Instructions to K. Y. Johnson, Lab. Book YQ-5/24/85	PG	73762	73762	R, H, I
PTX 499	U. of Ariz letter to P&G, 6/27/85	PG	73773	73773	R, H
PTX 500	Service Consultants letter to Norwich, 6/21/85	PG	73774	73775	R, H, A
PTX 501	U. of Ariz letter to P&G, 3/14/85	PG	73784	73789	R, H
PTX 502	U. of Ariz letter to P&G, 5/6/85	PG	73823	73823	R, H

Exhibit Number	Description	Bates Prefix	Bates Begin	Bates End	Teva USA's Objections
PTX 503	Notebook pages, Cyrus J. Hain	PG	73824	73825	R, H, A
PTX 504	VT1389-89 Total calcium	PG	73860	73877	R, H
PTX 505	Memo from R. p. D'Alonzo re Team Meeting Minutes, 7/16/85	PG	76654	76660	R, H, A, C
PTX 506	Sample 10057-2B submitted by A.M. Salvagno, 10/17/85	PG	76746	76981	R, H, C, U
PTX 507	Report by J.H. Powell for period ending 5/22/85	PG	77036	77036	R, H
PTX 508	Report by Kent Buckingham for period ending 9/6/85	PG	77098	77098	R, H
PTX 509	Report by D.F. Eastman for period ending 5/31/85	PG	77105	77105	R, H
PTX 510	Report by D. F. Eastman for period ending 6/14/85	PG	77106	77106	R, H
PTX 511	Memo: Kent Buckingham re: "Continued Preclinical Testing . . ."	PG	77107	77107	R, H
PTX 512	Report by D.F. Eastman for period ending 7/26/85	PG	77108	77109	R, H, C
PTX 513	Memo from R.P. D'Alonzo, 5/29/85	PG	94726	94731	R, H
PTX 514	Lab Notebook pages	PG	191296	191318	NP, I, R, H, A
PTX 515	Lab Notebook pages	PG	191319	191355	NP, I, R, H, A
PTX 516	Lab Notebook pages	PG	191356	191388	NP, I, R, H, A
PTX 517	Lab Notebook pages	PG	191389	191437	NP, I, R, H, A
PTX 518	Lab Notebook pages	PG	191438	191446	NP, I, R, H, A
PTX 519	Lab Notebook pages	PG	191447	191483	NP, I, R, H, A

SPECIFIC OBJECTIONS

- A = Authenticity (Fed. R. Evid. 901)
- B = Best Evidence Rule (Fed. R. Evid. 1002-1004)
- C = Improper compilation of separate documents. Teva USA reserves the right to further object to any specific document in the compilation P&G proposes to use.
- H = Hearsay (Fed. R. Evid. 801, 802)
- I = Incompleteness. The submitted exhibit appears to be an incomplete document and/or is missing pages.
- M = A copy of the exhibit was not provided by P&G or P&G failed to sufficiently describe the document. Teva USA reserves the right to object to the exhibit after obtaining a copy, reviewing a physical exhibit, or receiving a sufficient description from P&G.
- N = No objection, provided that the exhibit is introduced and authenticated by the appropriate sponsoring witness.
- Priv = Teva USA has requested the return of this privileged document which was inadvertently produced.
- E = Not qualified opinion, conclusion, or summary (Fed. R. Evid. 702, 703); lack of foundation for opinion, conclusion, or summary.
- NP = P&G provided the document far beyond the close of discovery and just prior to the due date of this Pre Trial order. Teva USA objects to these documents as inadmissible for this reason. Teva USA reserves to the right to make further objections and request further relief regarding P&G's belated document production once it has had a chance to more carefully review the documents.
- R = Relevance (Fed. R. Evid. 401, 402).
- S = Inadmissible as compromise and offers to compromise (Fed. R. Evid. 408)
- U = Unfair prejudice, confusion, waste of time, cumulative (Fed. R. Evid. 403).

Withdrawn = P&G has withdrawn the exhibit.